28.07
-0.385(-1.35%)
Currency In USD
| Previous Close | 28.45 |
| Open | 27.7 |
| Day High | 29.75 |
| Day Low | 27.17 |
| 52-Week High | 37.99 |
| 52-Week Low | 12.3 |
| Volume | 574,882 |
| Average Volume | 1.09M |
| Market Cap | 2.95B |
| PE | -11.05 |
| EPS | -2.54 |
| Moving Average 50 Days | 26.56 |
| Moving Average 200 Days | 26.23 |
| Change | -0.39 |
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 10, 2025 11:00 AM GMT
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
GlobeNewswire Inc.
Jun 09, 2025 11:00 AM GMT
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host co
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
GlobeNewswire Inc.
Jun 05, 2025 11:30 AM GMT
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly,